Clinical Dose-Response of Inflammation Formula Number 1 Granules Versus Traditional Decoction in the Treatment of Patients With Mild to Moderate Atopic Dermatitis: Protocol for a Multicenter Randomized Controlled Trial. - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/42397675
Explore the efficacy, dose-response, and convenience of IFN-1 granules versus traditional decoction for atopic dermatitis in this multicenter randomized trial.
This trial evaluates if IFN-1 granules offer efficacy comparable to traditional decoction, focusing on dose-response relationships and equivalence for atopic dermatitis.
An AI-augmented review of childhood atopic dermatitis biomarkers across genetic, immune, microbial, and metabolic domains. - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/42401802
Explore an AI-augmented review of childhood atopic dermatitis biomarkers across genetic, immune, microbial, and metabolic domains, identifying key biomarkers with strong evidence.
The study identifies 141 genome, 95 immunome, 57 microbiome, and 75 metabolome biomarkers, highlighting a model with strong evidence for eight specific biomarkers.
Beyond Inflammation: The Role of Oxidative Stress and Gut-Skin Axis Dysbiosis in the Pathogenesis of Immune-Mediated Skin Disorders and Potential Therapeutic Implications. - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/42278195
Discover how oxidative stress and gut-skin axis dysbiosis affect skin disorders, with therapies targeting ferroptosis and microbial metabolites for personalized care.
Oxidative stress, with biomarkers like malondialdehyde, and gut-skin axis dysbiosis contribute to skin disorders. Therapies targeting ferroptosis and microbial metabolites may personalize treatment.
Upadacitinib in the treatment of a patient with the triad of atopic dermatitis, vitiligo, and alopecia areata: a case report and literature review. - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/42338593
Explore potential of upadacitinib for severe atopic dermatitis, vitiligo, and alopecia areata, focusing on shared pathways. Further research required.
Upadacitinib is being explored for severe co-existing AD, vitiligo, and AA, targeting shared pathways. Further research is needed to confirm efficacy and safety.
Is Kaposi's sarcoma the end of the OX40/OX40L axis in atopic dermatitis? - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/42311687
Exploring the OX40/OX40L axis in atopic dermatitis: potential benefits offset by Kaposi's sarcoma risk. Strategies must balance efficacy and safety, considering rocatinlimab discontinuation.
The OX40/OX40L axis in atopic dermatitis shows potential, but Kaposi's sarcoma cases, including rocatinlimab discontinuation, highlight risks, necessitating refined strategies.
-
Barbara Honig1moRisks must always be weighed against potential benefits and thoroughly discussed with patients before choosing any therapy - especially biologics or advanced oral therapies in autoimmune diseases such as AD.